PIOGLITAZONE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Pioglitazone Hydrochloride patents expire, and when can generic versions of Pioglitazone Hydrochloride launch?
Pioglitazone Hydrochloride is a drug marketed by Accord Hlthcare, Annora Pharma, Aurobindo Pharma Ltd, Chartwell Rx, Corepharma, Macleods Pharms Ltd, Norvium Bioscience, Nostrum Labs Inc, Prinston Inc, Puracap Pharm Llc, Sandoz, Teva Pharms Usa, Torrent Pharms Ltd, and Zydus Pharms Usa Inc. and is included in twenty-two NDAs.
The generic ingredient in PIOGLITAZONE HYDROCHLORIDE is metformin hydrochloride; pioglitazone hydrochloride. There are forty-nine drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; pioglitazone hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PIOGLITAZONE HYDROCHLORIDE?
- What are the global sales for PIOGLITAZONE HYDROCHLORIDE?
- What is Average Wholesale Price for PIOGLITAZONE HYDROCHLORIDE?
Summary for PIOGLITAZONE HYDROCHLORIDE
Recent Clinical Trials for PIOGLITAZONE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Minnesota | Phase 2 |
Wuhan Union Hospital, China | Phase 2 |
University of Campinas, Brazil | Phase 4 |